Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilast (Otezla ) can reduce alcohol intake by more than half in people with severe alcohol use disorder.
February 27, 2023
LA JOLLA, CA A clinical trial carried out at Scripps Research has shown that apremilast, approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, cuts alcohol intake by more than half in people with severe alcohol use disorder (AUD). Collaborators at Oregon Health and Science University (OHSU) and other institutions also showed that, in mice, apremilast boosts activity in an area of the brain known to be involved in AUD.
The research was published online ahead of print by the Journal of Clinical Investigation on January 19, 2023.
We're incredibly excited to have found a drug that has such a large effect size on alcohol consumption, and with such good tolerability and safety at the same time, says co-senior author Barbara Mason, PhD, the Pearson Family Chair and Director of the Pearson Center for Alcohol and Addiction Research at Scripps Research.
About 29.5 million Americans meet the criteria for AUD, which encompasses the conditions known as alcohol abuse, alcohol dependence and alcohol addiction. Fewer than 10% of people with the disorder get any treatment, and an even smaller number are prescribed medication to treat AUD.
Mason is the director of the Translational Opportunities group for the Integrative Neuroscience Initiative on Alcoholism-NeuroImmune (INIA-NeuroImmune), a multidisciplinary, collaborative consortium funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to study the underlying biology of alcohol use disorder. In her role with INIA-NeuroImmune, Mason reviews research conducted by basic scientists in the consortium, and then identifies the most promising drug candidates for clinical trials.
INIA-NeuroImmune collaborators pinpointed apremilast sold under the brand name Otezla as a drug with the potential to treat AUD. The drug was known to block a molecule known as PDE4, which plays important roles in both immune and brain cell function. While its use in treating psoriasis is due to its immune function, basic scientific studies in mice had suggested that blocking PDE4 in the brain could reduce alcohol intake.
Mason launched a phase 2 trial, carried out entirely at the Pearson Center for Alcoholism and Addiction Research at Scripps Research, to study apremilast in humans. Among available PDE4 inhibitor medications, Mason chose apremilast because it had fewer of the gastrointestinal side effects associated with earlier PDE4 inhibitors such as rolipram or ibudalast. The trial enrolled 51 paid adult volunteers with severe AUD, none of whom were actively trying to consume less alcohol. For 14 days, each person took a daily pill of either apremilast or a placebo.
On average, participants consumed about five alcoholic drinks per day at the start of the study. People who received the placebo still drank nearly five drinks each day, while those who took apremilast reduced their alcohol intake to only about two drinks per day. In addition, apremilast decreased the percent of days that participants were classified as heavy drinkers. People who took apremilast reported anecdotally that they felt little impulse to drink and lacked the desire for alcohol that they usually had. Moreover, the drug was well tolerated with no participants discontinuing treatment due to gastrointestinal side effects
In this study, we saw that apremilast worked in mice. It worked in different labs, and it worked in people. This is incredibly promising for treatment of addiction in general, says co-senior author Angela Ozburn, PhD, associate professor of behavioral neuroscience in the OHSU School of Medicine and a research biologist with the Portland VA Health Care System.
Even with drugs currently approved by the FDA for alcohol use disorder, we usually see smaller effect sizes, says Mason. It's very unusual to get results like this, particularly in a severely affected population. This will need to move to larger, broader clinical trials now, but with this study, I think we've shown that this is an incredibly promising drug for alcohol use disorder.
In addition to Mason and Ozburn, authors of the study, Pre-clinical and clinical evidence for suppression of alcohol intake by apremilast, are Alan Beneze, Jessica Bess, Jenny Miller, Susan Quello, Amanda J. Roberts, Marisa Roberto, Farhad Shadan and Michael Skinner of Scripps Research; John C. Crabbe, Evan J. Firsick, Kolter B. Grigsby, Pamela Metten and Kayla G. Townsley of Oregon Health & Science University; Heather C. Aziz, Regina A. Mangieri and Richard A. Morrisett of The University of Texas at Austin; Howard C. Becker and Marcelo F. Lopez of Medical University of South Carolina; Toby K. Eisenstein and Joseph J. Meissler of Temple University; and John M. Light of Oregon Research Institute.
This work was supported by funding from the National Institutes of Health (AA016651, AA013519, AA010760, AA07468, and AA027692, U01 AA013498, DA013429, P60AA06420 U01AA025476); the US Department of Veterans Affairs Grants (BX000313, BX004699, and IK2 BX002488), and a gift from the John R. Andrews Family.
Neurological Disorders Neuroscience Mason, Barbara
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
13/05/2026
New Adobe Premiere Color Grading Mode Accelerated on NVIDIA GPUs
Joel Pennington May 13, 2026
0 Comments
New NVIDIA RTX-accelerated features streamlin...
13/05/2026
Grass Valley announced that dB Broadcast has delivered new IP-based outside broadcast (OB) trucks for Cloudbass, featuring Grass Valley LDX 100 Series cameras a...
13/05/2026
Ikegami will exhibit the latest additions to its wide range of broadcast production cameras, control units, viewfinders and monitors on stand 5D3-1 at Broadcast...
13/05/2026
FISE, working with the founding members of the XR Sports Alliance (XRSA), Accedo, Qualcomm Technologies, Inc. and HBS, have collaborated to develop an immersive...
13/05/2026
Canon Unveils New EOS R6 V Full-Frame EOS Camera and RF20-50mm F4 L IS USM PZ Bu...
13/05/2026
Boston Conservatory at Berklee Honors Beth Morrison and Moses Pendleton at Comme...
13/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
13/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
13/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
13/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
13/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
13/05/2026
Creative software developer Foundry today announced the latest developments on Nuke Stage. A purpose-built application for end-to-end virtual production and in-...
13/05/2026
A definitive portrait of one of Ireland's most influential musicians
New TV documentary airs Monday 18 May on RT One and RT Player at 9.35pm
Watch the...
13/05/2026
Agentic AI is changing the way users get work done. Following the success of OpenClaw, the community is embracing new open source agentic frameworks. The latest...
13/05/2026
Reinforcement-learning agents - AI systems that learn by trial and error - can c...
12/05/2026
Beyond the Hype: A Strategic Post-Hoc Analysis of NAB 2026 If NAB Show 2026 had an underlying theme, it was a quiet, industry-wide pivot from the high-energy sp...
12/05/2026
Guntermann and Drunck (G&D), a Panoptec Technologies Group company, and CT Square, led by Chandresh Shah, have announced a joint venture to distribute G&D and V...
12/05/2026
With 30 days until the start of the FIFA World Cup 2026, Telemundo, the exclusive Spanish-language home of the tournament in the United States, has announced th...
12/05/2026
The NHL has announced the return of Stanley Pup for its third consecutive year, a 90-minute special featuring adoptable rescue dogs competing on a miniature rin...
12/05/2026
NBCUniversal presented its 2026 Upfront to advertisers at Radio City Music Hall, detailing upcoming programming across NBC, Peacock, Bravo, and Versant properti...
12/05/2026
FOX Sports has announced funding for the Fandom and Social Connection Initiative at Harvard Kennedy School's Shorenstein Center on Media, Politics, and Publ...
12/05/2026
TNDV and Live Media, both divisions of Live Media Group, supported live broadcast coverage around NCAA Final Four weekend in Indianapolis, including the March M...
12/05/2026
The European Football Alliance (EFA) has announced a content distribution agreement with Fubo Sports Network, the free ad-supported streaming TV (FAST) channel ...
12/05/2026
For the first time, Spanish-speaking fans in the U.S. will have two separate tel...
12/05/2026
CP Communications led a comprehensive spectrum management initiative on behalf of Churchill Downs during Kentucky Derby week, coordinating RF assets across the ...
12/05/2026
LiveU has announced a strategic partnership with DRONERESPONDERS, a 501(c)3 non-...
12/05/2026
Open Broadcast Systems has announced that BMC TV, a specialist in IP transport of broadcast content, has selected the Open Broadcast Systems 5G Flyaway solution...
12/05/2026
NEP Europe, part of NEP Group, has announced it will deliver broadcast solutions...
12/05/2026
Grass Valley has announced continued collaboration with Ravensbourne University ...
12/05/2026
Stats Perform has announced the launch of Opta Pulse, an AI-assisted video creation and distribution platform for leagues, rights holders, and broadcasters. The...
12/05/2026
FOX Sports has announced a collaboration with Sesame Workshop to integrate Sesame Street characters into FOX Sports' FIFA World Cup 2026 programming. Conten...
12/05/2026
To date, NHL Productions has produced 19 broadcasts with commentary in American Sign Language
NHL in ASL (American Sign Language) may be just one show, but the...
12/05/2026
Google's Brian Albert: creators, athletes, highlights, nostalgia, second-scr...
12/05/2026
A still from Past Lives by Celine Song, an official selection of the Premieres program at the 2023 Sundance Film Festival. (Courtesy of Sundance Institute | p...
12/05/2026
Spotify is where fans and artists come together, turning discovery into somethin...
12/05/2026
Features patented Marco-MMC clocking technology
Black Lion Audio's latest release combines the company's expertise in clocking with their renowned p...
12/05/2026
New Track Panel, sequencer upgrades & more
Following their recent public beta release, Reason Studios have announced the full release of Reason 14. With the...
12/05/2026
One month to go! SBS reveals expansive FIFA World Cup 2026 lineup beyond the pi...
12/05/2026
Rohde & Schwarz presents its advanced solutions for power electronics testing at...
12/05/2026
aconnic AG (ISIN: DE000A0LBKW6), Munich, has developed a modified fund raising p...
12/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
12/05/2026
Tyrell Corporation, specialists in high-end live sports and entertainment broadcasts, was tasked with delivering compelling broadcast coverage of premier equest...
12/05/2026
Registration is now open for IBC2026 as the global media, entertainment and technology community prepares to converge on the RAI Amsterdam from 11 14 September ...
12/05/2026
Ross Video, a global leader in live video production technology, will present its latest innovations and integrated production workflows at BroadcastAsia 2026, ...
12/05/2026
500 selected leaders from around the world across start-ups, corporates, and venture capital. Over 50bn in assets under management among attending investors, a...
Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilast (Otezla ) can reduce alcohol intake by more than half in people with severe alcohol use disorder.
